Advertisement
Screener

ASTRAZENECA PLC (AZN) Form 6-K: Report of foreign private issuer, 2017

2.4 / 5 stars · 19/40 Roast Me

Add as a preferred source on Google

ASTRAZENECA PLC Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2017-12-28: Form 6-K; Period of report 2017-12-28; Description DIRECTOR/PDMR SHAREHOLDING; Document a4360a.htm.
  • 2017-12-18: Form 6-K; Period of report 2017-12-18; Description FDA ACCEPTS TAGRISSO SUBMISSION FOR 1ST-LINE NSCLC; Document a5825z.htm.
  • 2017-12-15: Form 6-K; Period of report 2017-12-15; Description DIRECTOR/PDMR SHAREHOLDING; Document a5064z.htm.
  • 2017-12-01: Form 6-K; Period of report 2017-12-01; Description BLOCK LISTING INTERIM REVIEW; Document a1746y.htm.
FiledFormPeriod of reportDescriptionDocument
2017-12-286-K2017-12-28DIRECTOR/PDMR SHAREHOLDINGa4360a.htm
2017-12-186-K2017-12-18FDA ACCEPTS TAGRISSO SUBMISSION FOR 1ST-LINE NSCLCa5825z.htm
2017-12-156-K2017-12-15DIRECTOR/PDMR SHAREHOLDINGa5064z.htm
2017-12-016-K2017-12-01BLOCK LISTING INTERIM REVIEWa1746y.htm
2017-12-016-K2017-12-01TOTAL VOTING RIGHTSa1739y.htm
2017-11-286-K2017-11-28EMA ACCEPTS TAGRISSO SUBMISSION FOR 1ST-LINE NSCLCa6531x.htm
2017-11-276-K2017-11-27AZ SUBMITS TAGRISSO IN JAPAN FOR 1ST-LINE NSCLCa5612x.htm
2017-11-156-K2017-11-14AZ FASENRA RECEIVES FDA APPROVAL FOR SEVERE ASTHMAa5116w.htm
2017-11-136-K2017-11-13BENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMAa1880w.htm
2017-11-096-K2017-11-09AZN: YEAR-TO-DATE AND Q3 2017 RESULTS ANNOUNCEMENTa9880v.htm
2017-11-016-K2017-11-01TOTAL VOTING RIGHTSa2921v.htm
2017-11-016-K2017-11-01ASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEALa2163v.htm
2017-11-016-K2017-11-01ASTRAZENECA TRALOKINUMAB UPDATE IN SEVERE ASTHMAa1836v.htm
2017-10-316-K2017-10-31US FDA APPROVES ASTRAZENECA'S CALQUENCE FOR MCLa1653v.htm
2017-10-236-K2017-10-23US FDA APPROVES BYDUREON BCISE FOR TYPE-2 DIABETESa2731u.htm
2017-10-236-K2017-10-23AZ AND MSD RAPIDLY ADVANCE LYNPARZA IN JAPANa2987u.htm
2017-10-186-K2017-10-18FDA PRIORITY REVIEW FOR LYNPARZA IN BREAST CANCERa8811t.htm
2017-10-176-K2017-10-17FDA ACCEPTS SBLA FILE FOR IMFINZI; PRIORITY REVIEWa7454t.htm
2017-10-106-K2017-10-10FDA GRANTS TAGRISSO BTD FOR 1ST-LINE EGFR NSCLCa0083t.htm
2017-10-026-K2017-10-02TOTAL VOTING RIGHTSa4428s.htm
2017-09-266-K2017-09-26DIRECTOR/PDMR SHAREHOLDINGa8487r.htm
2017-09-146-K2017-09-14ASPEN ACQUIRES REMAINING RIGHTS TO AZ ANAESTHETICSa7462q.htm
2017-09-116-K2017-09-11IMFINZI SUPERIOR PFS IN STAGE III LUNG CANCERa3074q.htm
2017-09-116-K2017-09-11TAGRISSO POTENTIAL STANDARD OF CARE IN LUNG CANCERa3076q.htm
2017-09-076-K2017-09-07CELGENE AND AZ UPDATE ON FUSION TRIAL PROGRAMMEa1341q.htm
2017-09-076-K2017-09-07AZ DUAKLIR IMPROVES LUNG FUNCTION IN COPD PATIENTSa0429q.htm
2017-09-076-K2017-09-07AZ TEZEPELUMAB CUTS EXACERBATIONS IN SEVERE ASTHMAa0427q.htm
2017-09-056-K2017-09-05DIRECTORATE CHANGEa7509p.htm
2017-09-016-K2017-09-01TOTAL VOTING RIGHTSa6150p.htm
2017-08-176-K2017-08-17LYNPARZA GETS BROAD FDA APPROVAL IN OVARIAN CANCERa3481o.htm
2017-08-166-K2017-08-16DIRECTORATE CHANGEa0964o.htm
2017-08-146-K2017-08-14HOLDING(S) IN COMPANYa9329n.htm
2017-08-106-K2017-08-10PUBLICATION OF A PROSPECTUSa6730n.htm
2017-08-026-K2017-08-02AZ ACALABRUTINIB SUBMISSION ACCEPTED BY US FDAa8504m.htm
2017-08-016-K2017-08-01TOTAL VOTING RIGHTSa7609m.htm
2017-08-016-K2017-08-01BTD FOR AZS ACALABRUTINIB IN MANTLE CELL LYMPHOMAa6982m.htm
2017-07-316-K2017-07-31IMFINZI GRANTED BTD BY US FDA FOR STAGE III NSCLCa5379m.htm
2017-07-286-K2017-07-28DIRECTOR/PDMR SHAREHOLDINGa4363m.htm
2017-07-276-K2017-07-27TAGRISSO SIGNIFICANTLY IMPROVES FLAURAa2561m.htm
2017-07-276-K2017-07-27AZ REPORTS INITIAL RESULTS FROM MYSTIC LUNG TRIALa2559m.htm
2017-07-276-K2017-07-27AZ & MERCK ESTABLISH STRATEGIC ONCOLOGY DEALa2553m.htm
2017-07-276-K2017-07-27ASTRAZENECA PLC - H1 2017 RESULTSa2543m.htm
2017-07-266-K2017-07-26FASLODEX RECEIVES EU APPROVAL FOR 1L BREAST CANCERa2019m.htm
2017-07-216-K2017-07-21HOLDING(S) IN COMPANYa7928l.htm
2017-07-036-K2017-07-03TOTAL VOTING RIGHTSa9489j.htm
2017-07-036-K2017-07-03AZ COMPLETES SELOKEN AGREEMENT WITH RECORDATIa8473j.htm
2017-07-036-K2017-07-03AZ COMPLETES ZOMIG DIVESTMENT WITH GRUNENTHALa8470j.htm
2017-06-236-K2017-06-23FASLODEX CHMP POSITIVE OPINION IN 1L BREAST CANCERa0374j.htm
2017-06-126-K2017-06-12FORM 6-Kdp77198_6k.htm
2017-06-076-K2017-06-07AZ AGREEMENT WITH GRUNENTHAL FOR RIGHTS TO ZOMIGa3794h.htm
2017-06-066-K2017-06-06ASTRAZENECA PRICES A $2BN BOND ISSUEa2067h.htm
2017-06-056-K2017-06-05LYNPARZA: SIGNIFICANT PFS IN BRCAM BREAST CANCERa0896h.htm
2017-06-016-K2017-06-01TOTAL VOTING RIGHTSa8926g.htm
2017-06-016-K2017-06-01BLOCK LISTING INTERIM REVIEWa8911g.htm
2017-05-316-K2017-05-31DIRECTORATE CHANGEa6013g.htm
2017-05-246-K2017-05-24DIRECTOR/PDMR SHAREHOLDINGa1246g.htm
2017-05-236-K2017-05-23BYDUREON EXSCEL TRIAL MEETS T2D SAFETY OBJECTIVEa9300f.htm
2017-05-226-K2017-05-22AZ AGREEMENT WITH RECORDATI FOR SELOKEN IN EUROPEa7680f.htm
2017-05-166-K2017-05-16DIRECTOR/PDMR SHAREHOLDINGa3010f.htm
2017-05-126-K2017-05-12IMFINZI SIGNIFICANT PFS - UNRESECTABLE LUNG CANCERa9672e.htm
2017-05-106-K2017-05-10AZ UPDATES ON TRALOKINUMAB TRIAL IN SEVERE ASTHMAa6724e.htm
2017-05-026-K2017-05-02TOTAL VOTING RIGHTSa9225d.htm
2017-05-026-K2017-05-02DURVALUMAB RECEIVES US FDA ACCELERATED APPROVALa7991d.htm
2017-04-276-K2017-04-27RESULT OF AGMa6160d.htm
2017-04-276-K2017-04-27ASTRAZENECA: Q1 2017 RESULTSa4745d.htm
2017-04-256-K2017-04-25TAGRISSO RECEIVES FULL APPROVAL IN THE EUa2765d.htm
2017-04-036-K2017-04-03TOTAL VOTING RIGHTSa3866b.htm
2017-03-316-K2017-03-31AZ COMPLETES AGREEMENT WITH TERSERA THERAPEUTICSa0970b.htm
2017-03-316-K2017-03-31TAGRISSO (OSIMERTINIB) RECEIVES FDA FULL APPROVALa1315b.htm
2017-03-286-K2017-03-28DIRECTOR/PDMR SHAREHOLDINGa7881a.htm
2017-03-276-K2017-03-27DIRECTOR/PDMR SHAREHOLDINGa6396a.htm
2017-03-176-K2017-03-17US FDA ISSUES CRL FOR ZS-9 IN HYPERKALAEMIAa7828z.htm
2017-03-166-K2017-03-16NOTICE OF AGMa6791z.htm
2017-03-166-K2017-03-166-Kd354862d6k.htm
2017-03-156-K2017-03-15LYNPARZA PFS IN BRCA OVARIAN MAINTENANCE THERAPYa5122z.htm
2017-03-086-K2017-03-08FILING OF FORM 20-F WITH SECa8045y.htm
2017-03-076-K2017-03-07ANNUAL FINANCIAL REPORTa7700y.htm
2017-03-066-K2017-03-06DIRECTORATE CHANGEa5419y.htm
2017-03-036-K2017-03-03ALLIANCE WITH SANOFI PASTEUR FOR MEDI8897a4166y.htm
2017-03-016-K2017-03-01TOTAL VOTING RIGHTSa2725y.htm
2017-03-016-K2017-03-01FDA APPROVES ONCE DAILY QTERN FOR TYPE 2 DIABETESa0247y.htm
2017-02-246-K2017-02-24CHMP POSITIVE OPINION FOR ZS-9 IN HYPERKALAEMIAa8214x.htm
2017-02-216-K2017-02-21AZ LICENSES ZOLADEX TO TERSERA FOR THE US & CANADAa2531x.htm
2017-02-176-K2017-02-17LYNPARZA POSITIVE IN METASTATIC BRCA BREAST CANCERa1624x.htm
2017-02-166-K2017-02-16SILIQ (BRODALUMAB) APPROVED BY US FDAa0894x.htm
2017-02-026-K2017-02-02AZN: FY16 AND Q4 2016 RESULTSa8087v.htm
2017-02-016-K2017-02-01TOTAL VOTING RIGHTSa7766v.htm
2017-01-266-K2017-01-26SYMBICORT GRANTED PAEDIATRIC EXCLUSIVITY IN THE USa2069v.htm
2017-01-176-K2017-01-17AZ 1ST-LINE LUNG CANCER IMMUNO-ONCOLOGY PROGRAMMEa3291u.htm
2017-01-036-K2017-01-03TOTAL VOTING RIGHTSa2327t.htm
Advertisement